Publicaciones en las que colabora con Lucía López Corral (21)

2024

  1. Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells

    Cytotherapy

2023

  1. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

  2. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

  3. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

    Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580

2022

  1. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

    Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067

  2. CT-169 Cytokine Release Syndrome After Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide: Time of Onset Matters

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S437-S438

  3. Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review

    Advances in Rheumatology, Vol. 62, Núm. 1

  4. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

    Journal of hematology & oncology, Vol. 15, Núm. 1, pp. 54

  5. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

2019

  1. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

    Bone Marrow Transplantation

2018

  1. Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting

    Medical Oncology, Vol. 35, Núm. 6

2017

  1. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation

    Bone Marrow Transplantation

2016

  1. Biomarkers in ocular chronic graft versus host disease: Tear cytokine- and chemokine-based predictive model

    Investigative Ophthalmology and Visual Science, Vol. 57, Núm. 2, pp. 746-758

  2. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: Results of a multicenter study

    Bone Marrow Transplantation

2015

  1. GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT

    Bone Marrow Transplantation, Vol. 50, Núm. 1, pp. 121-126

  2. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant

    British Journal of Haematology, Vol. 169, Núm. 5, pp. 719-725

  3. Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

    Leukemia Research, Vol. 39, Núm. 8, pp. 828-834

2014

  1. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

    Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

2013

  1. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

    Haematologica, Vol. 98, Núm. 3, pp. 437-443

  2. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate

    Haematologica, Vol. 98, Núm. 4, pp. 526-532